15 Hrs
المصدر:
The Boston Globe
المصدر: The Boston Globe
15 HrsThe Boston Globe
المصدر: The Boston Globe
15 Hrsجاهز للتشغيل
جاهز للتشغيل
A late-stage clinical trial has shown that a personalized mRNA cancer vaccine, combined with Merck’s Keytruda, slowed melanoma recurrence and spread in patients whose tumors had been surgically removed. The trial involved over 1,100 participants and indicated improvements in preventing melanoma’s return and metastasis, with results considered clinically meaningful. If approved, this treatment could mark a significant advancement in personalized cancer therapies and demonstrate the potential of mRNA technology beyond infectious diseases.
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading